Narula Nupoor, Tester David J, Paulmichl Anna, Maleszewski Joseph J, Ackerman Michael J
Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Pediatr Cardiol. 2015 Apr;36(4):768-78. doi: 10.1007/s00246-014-1082-4. Epub 2014 Dec 13.
Annually, thousands of sudden deaths in individuals under 35 years remain unexplained following comprehensive medico-legal autopsy. Previously, post-mortem genetic analysis by Sanger sequencing of four major cardiac channelopathy genes revealed that approximately one-fourth of these autopsy-negative sudden unexplained death in the young (SUDY) cases harbored an underlying mutation. However, there are now over 100 sudden death-predisposing cardiac channelopathy-, cardiomyopathy-, and metabolic disorder-susceptibility genes. Here, we set out to determine whether post-mortem whole exome sequencing (WES) is an efficient strategy to detect ultra-rare, potentially pathogenic variants. We performed post-mortem WES and gene-specific analysis of 117 sudden death-susceptibility genes for 14 consecutively referred Caucasian SUDY victims (average age at death 17.4 ± 8.6 years) to identify putative SUDY-associated mutations. On average, each SUDY case had 12,758 ± 2,016 non-synonymous variants, of which 79 ± 15 localized to these 117 genes. Overall, eight ultra-rare variants (seven missense, one in-frame insertion) absent in three publically available exome databases were identified in six genes (three in TTN, and one each in CACNA1C, JPH2, MYH7, VCL, RYR2) in seven of 14 cases (50 %). Of the seven missense alterations, two (T171M-CACNA1C, I22160T-TTN) were predicted damaging by three independent in silico tools. Although WES and gene-specific surveillance is an efficient means to detect rare genetic variants that might underlie the pathogenic cause of death, accurate interpretation of each variant is challenging. Great restraint and caution must be exercised otherwise families may be informed prematurely and incorrectly that the root cause has been found.
每年,在35岁以下人群中,数千例猝死在经过全面的法医学尸检后仍无法解释。此前,通过桑格测序对四个主要心脏离子通道病基因进行的死后基因分析显示,这些尸检阴性的年轻不明原因猝死(SUDY)病例中,约四分之一存在潜在突变。然而,目前有超过100个与猝死相关的心脏离子通道病、心肌病和代谢紊乱易感性基因。在此,我们着手确定死后全外显子测序(WES)是否是检测超罕见、潜在致病变异的有效策略。我们对14例连续转诊的白种人SUDY受害者(平均死亡年龄17.4±8.6岁)进行了死后WES和117个猝死易感性基因的基因特异性分析,以确定与SUDY相关的推定突变。平均而言,每个SUDY病例有12,758±2,016个非同义变异,其中79±15个定位于这117个基因。总体而言,在14例病例中的7例(50%)中,在6个基因(TTN中有3个,CACNA1C、JPH2、MYH7、VCL、RYR2各有1个)中鉴定出8个在三个公开可用外显子数据库中不存在的超罕见变异(7个错义变异,1个框内插入变异)。在7个错义改变中,有2个(T171M - CACNA1C、I22160T - TTN)被三个独立的计算机模拟工具预测为有害。尽管WES和基因特异性监测是检测可能构成死亡致病原因的罕见遗传变异的有效手段,但对每个变异的准确解释具有挑战性。必须极其克制和谨慎,否则可能会过早且错误地告知家属已找到根本原因。